Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel
NASDAQ:TCRX

TScan Therapeutics Q3 2026 Earnings Date & Estimates

TScan Therapeutics logo
$0.21 -0.01 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$0.21 +0.00 (+1.61%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TScan Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from TScan Therapeutics in Q3 2026

TScan Therapeutics is expected to post earnings of -$0.18 per share on revenue of $0.46 million. In the same quarter a year earlier TScan Therapeutics reported -$0.28 per share on revenue of $2.51 million. TScan Therapeutics last reported on August 12, 2026, posting -$0.23 per share and beating the -$0.2534 consensus estimate. TScan Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.18
Expected Revenue
$0.46 million
Prior-Year EPS
-$0.28
Prior-Year Revenue
$2.51 million
Expected Revenue Growth
-81.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.23 (Beat by +$0.0234)
Last Quarter Revenue
$1.05 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

TScan Therapeutics Q3 2026 Earnings FAQ

TScan Therapeutics (NASDAQ:TCRX) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

TScan Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect TScan Therapeutics to post earnings of -$0.18 per share for Q3 2026.

The consensus revenue estimate for TScan Therapeutics is $0.46 million for Q3 2026.

TScan Therapeutics Earnings Headlines

TScan Therapeutics consensus price target decreased by 55.56% to $2.72
September 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tscan-therapeutics-consensus-price-target-decreased-by-55-56-to-2-72/ar-AA2cjuKv
Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/wedbush-downgrades-tscan-therapeutics-tcrx-to-neutral-from-outperform/ar-AA2bwA9B
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.tc pixel
October 14 at 1:00 AM  |  Awesomely (Ad)
TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%
September 2, 2026  |  rttnews.comhttps://www.rttnews.com/3687878/tscan-therapeutics-reorganizes-to-focus-on-solid-tumor-program-to-cut-75-jobs-stock-tumbles-11.aspx
TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/science/general/tscan-therapeutics-cuts-workforce-by-75-and-shifts-focus-to-solid-tumor-program/ar-AA2bqfIn
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
September 2, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/09/61580674/tscan-reorganizes-pipeline-priorities-implements-workforce-reduction
See More TScan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email.

About TScan Therapeutics

TScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell therapies for patients with cancer. The company’s approach is designed to harness the ability of T cells to recognize cancer-associated antigens presented on the surface of tumor cells, including targets that may be difficult to address with other forms of cell therapy.

TScan’s pipeline includes TCR-engineered therapies for both hematologic malignancies and solid tumors. Its TSC-100 and TSC-101 programs are being developed for patients undergoing allogeneic hematopoietic stem cell transplantation, with the goal of targeting minor histocompatibility antigens and reducing the risk of disease relapse. The company is also advancing a portfolio of TCR-T product candidates directed at tumor-associated antigens in solid tumors.

Founded in 2018 and headquartered in Waltham, Massachusetts, TScan conducts its research and clinical development activities primarily in the United States. The company is led by President and Chief Executive Officer David Southwell and is listed on the Nasdaq under the symbol TCRX.

View TScan Therapeutics Profile
Earnings Tools